Moderna Is Up 94% This Year: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?

The post Moderna Is Up 94% This Year: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax? appeared first on 24/7 Wall St..

• Moderna (MRNA) jumps 9% today to $57, extending a +94% YTD rally—the best performer in the vaccine cohort, crushing Pfizer (PFE) at +4% and Novavax (NVAX) at +41%.
• Moderna's leadership restructuring signals operational readiness for three planned vaccine launches in 2027-2028.
• Moderna stock carries execution risk: a $1.34B Q1 loss from patent litigation, Wall Street's "Reduce" consensus.
• Watch the June 18 FDA advisory committee vote on mFlusiva and August 5 PDUFA decision for mRNA-1010; either setback could test the sustainability of Moderna's 2026 rally above the.
• Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Moderna didn't make the cut. Grab the names FREE today.

Moderna (NASDAQ:MRNA) stock is jumping again. Shares are up 9% today, trading near $57 in the Tuesday afternoon session. That extends a remarkable 2026 run for the mRNA pioneer.

The move pushes Moderna stock to +94% year to date (YTD), easily the best performance in the major vaccine cohort. By comparison, Pfizer (NYSE:PFE) stock is up 4% YTD, and Novavax (NASDAQ:NVAX) stock sits at 41%. Moderna is decisively ahead of both peers.

Today’s catalyst is corporate, not clinical. Moderna announced a leadership restructuring to prepare for a wave of planned product launches in 2027 and 2028, and traders are treating it as a credibility signal for the pipeline.

Restructuring Frames a 2027-2028 Launch Pipeline

Moderna disclosed an expanded role for President Stephen Hoge and named Ester Banque as Chief Commercial Officer. Hoge now oversees R&D, Manufacturing, and Commercial operations across three franchises, a structure designed for commercial scale rather than research-stage biotech.

The reorganization lines up with a planned slate of up to three product launches by 2027-2028, including a flu-plus-COVID combination vaccine, a seasonal flu vaccine, and a norovirus vaccine. Investors are reading the move as Moderna preparing the operational backbone needed to commercialize multiple vaccines simultaneously.

The day’s enthusiasm also rides on a recently approved EU label for mCOMBRIAX, the world’s first flu-plus-COVID combo vaccine, and a key upcoming Prescription Drug User Fee Act (PDUFA) date of August 5 for the seasonal flu candidate mRNA-1010. Both reinforce the narrative that 2026 is the setup year and 2027-2028 is the payoff window.

Moderna Versus Pfizer and Novavax: The 2026 Scoreboard

The YTD scoreboard answers the headline question directly. Moderna stock at +94% is ahead of Novavax stock and crushing Pfizer stock in 2026 so far. The dispersion reflects three very different business profiles within one industry label.

Pfizer is a diversified pharma giant where vaccines are one slice of a large revenue book. The company’s Q1 2026 revenue was $14.45 billion, up 5% year over year (YoY), with Comirnaty revenue down 59% and Paxlovid revenue down 63%, offset by launched and acquired products. Pfizer’s 7% dividend yield anchors a steadier, lower-beta profile, which limits both upside and downside in a momentum tape.

Meanwhile, Novavax is in transition. The company is leaning on a Matrix-M adjuvant licensing model, including a $30 million upfront payment from Pfizer with up to $500 million in milestones, and Q1 2026 revenue of $139.51 million easily topped consensus. However, that royalty-driven model carries lower revenue scale than Moderna’s product-led path.

The Caution Inside a 94% Rally

Moderna stock isn’t without baggage. The company’s Q1 2026 included an $878 million non-recurring litigation charge tied to the Arbutus/Genevant patent settlement, which widened the GAAP loss to $1.34 billion. Wall Street has been slow to embrace the rebound, with an analyst average 1-year MRNA price target of $37 and a consensus rating of Reduce.

Zoom out and Moderna stock is still down 74% over five years, well below its pandemic-era peaks. The 2026 run is a rebound, not a return to those highs, and the 2027-2028 launch slate carries real execution and regulatory risks.

What to Watch Next

The near-term event to look for is the FDA advisory committee vote scheduled for June 18 on mFlusiva for adults 50 and older. A constructive panel readout could reinforce today’s bid, while a mixed verdict may test how much of the 94% YTD gain is priced for perfection.

Investors can watch whether Moderna stock holds the $50 zone into the June 18 advisory committee vote and the August 5 PDUFA decision. Until then, feel free to size your share vaccine-stock positions with due caution and moderation.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Moderna didn’t make the cut. Grab the names FREE today.

The post Moderna Is Up 94% This Year: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax? appeared first on 24/7 Wall St..